Forian Inc (FORA)vsNovartis AG ADR (NVS)
FORA
Forian Inc
$2.16
+0.23%
HEALTHCARE · Cap: $67.33M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $280.79B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 187209% more annual revenue ($56.67B vs $30.26M). NVS leads profitability with a 24.7% profit margin vs -9.5%. FORA appears more attractively valued with a PEG of 0.94. NVS earns a higher WallStSmart Score of 51/100 (C-).
FORA
Hold39
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FORA.
Margin of Safety
-52.2%
Fair Value
$109.78
Current Price
$147.85
$38.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37.0% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -9.6% — below average capital efficiency
Earnings declined 89.1%
Currently unprofitable
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : FORA
The strongest argument for FORA centers on Revenue Growth, PEG Ratio, Price/Book. Revenue growth of 37.0% demonstrates continued momentum. PEG of 0.94 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bear Case : FORA
The primary concerns for FORA are Market Cap, Return on Equity, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
FORA profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
FORA carries more volatility with a beta of 0.99 — expect wider price swings.
FORA is growing revenue faster at 37.0% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 39/100), backed by strong 24.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Forian Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Forian Inc. provides a suite of software solutions, data management capabilities, proprietary data, and predictive analytics to optimize and measure operational, clinical, and financial performance for clients in the health and cannabis industries, as well as dispensaries. , cannabis growers, manufacturers, and distributors. The company is headquartered in Newtown, Pennsylvania.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?